Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096159 · ClinicalTrials.gov registry record · NA
Prophylactic Antibiotics or Placebo After Hypospadias Repair
A NA study of Hypospadias, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Active
- Registry status
- NA
- Development phase
- 93
- Enrollment target
- 2
- Study locations
NCT02096159: Active NA study of Hypospadias, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
NCT02096159 is a NA study of Hypospadias that is active but no longer recruiting, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 93 participants, below the 121-participant average among 3 other Hypospadias trials with a reported enrollment target (23% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02096159, a NA study of Hypospadias, is active but no longer recruiting, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to determine if routine use of prophylactic (preventive) antibiotics after repair of mid-to-distal hypospadias is beneficial.
Primary Outcome
Urinary tract infection; cellulitis/wound infection
Conditions Studied
Interventions
- OTHER placebo
- DRUG trimethoprim-sulfamethoxazole
Study Locations (2)
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago - Chicago
Ontario
- The Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-03 |
| Est. Completion | 2025-08 |
| Phase | NA |
What the registry record for NCT02096159 still lists
NCT02096159 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 121-participant average among 3 other Hypospadias trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Hypospadias appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02096159 reports a single indexed study location in Illinois, Ontario.
Frequently Asked Questions
What is clinical trial NCT02096159 about?
NCT02096159 is a clinical study titled "Prophylactic Antibiotics or Placebo After Hypospadias Repair". The primary purpose of this study is to determine if routine use of prophylactic (preventive) antibiotics after repair of mid-to-distal hypospadias is beneficial.
What is the current status of trial NCT02096159?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 93 participants. The study started on 2014-03. Estimated completion is 2025-08.
What conditions does trial NCT02096159 study?
This clinical trial studies the following conditions: Hypospadias.
What interventions are being tested in trial NCT02096159?
The interventions under investigation include: placebo (OTHER), trimethoprim-sulfamethoxazole (DRUG).
Who is sponsoring clinical trial NCT02096159?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02096159 being conducted?
This trial has 2 study locations across Illinois, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypospadias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia